진해제 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The Antitussive Drugs Market size is expected to reach USD 2.58 Billion in 2034 from USD 1.73 Billion (2025) growing at a CAGR of 4.59% during 2026-2034.

The global antitussive drugs market has grown steadily due to the increasing prevalence of respiratory conditions and seasonal illnesses that cause persistent coughing. Antitussive drugs, commonly known as cough suppressants, are used to reduce coughing by acting on the cough reflex in the brain or throat. These medications are widely used in treating symptoms associated with colds, flu, bronchitis, and other respiratory infections. Growing awareness about respiratory health has contributed to increased demand for these medications.

Market growth is driven by several factors, including the rising incidence of respiratory infections and environmental pollution. Changing weather conditions and urban air pollution can aggravate respiratory conditions, leading to increased use of cough suppressants. In addition, the availability of both prescription and over-the-counter antitussive medications has expanded consumer access to treatment options. Pharmaceutical companies are also developing improved formulations that provide faster symptom relief and longer-lasting effects.

The future of the antitussive drugs market appears positive as healthcare awareness continues to increase worldwide. Innovations in drug formulations and combination therapies may enhance treatment effectiveness for respiratory symptoms. Expanding pharmaceutical distribution networks and growing access to healthcare services in emerging markets are also expected to support market growth. As respiratory illnesses remain common globally, demand for effective cough suppression treatments is likely to continue.

MARKET SEGMENTATION

By Drug

• Benzonatate
• Dextromethorphan

By Drug Class

• Centrally Acting Drugs
• Peripherally Acting Drugs
• Others

By Route of Administration

• Oral
• Inhalational
• Others

By Dosage Form

• Syrup
• Tablet
• Others

By Indication

• Cold Symptoms
• Pain
• Cough
• Others

By Product Type

• Over-The-counter (OTC)
• Prescription Drug

By Age Group

• Pediatric
• Adult
• Geriatric

By End-Users

• Hospitals
• Specialty Clinics
• Homecare
• Others

By Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

COMPANIES PROFILED

• F HoffmannLa Roche Ltd, Pfizer Inc, Novartis AG, GlaxoSmithKline plc, Sanofi, Johnson Johnson Private Limited, Teva Pharmaceutical Industries Ltd, Sun Pharmaceutical Industries Ltd, Mylan NV, AstraZeneca, Bayer AG, Cipla Inc, Aurobindo Pharma, Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals LLC
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL ANTITUSSIVE DRUGS MARKET: BY DRUG 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Drug
• 4.2. Benzonatate Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Dextromethorphan Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL ANTITUSSIVE DRUGS MARKET: BY DRUG CLASS 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Drug Class
• 5.2. Centrally Acting Drugs Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Peripherally Acting Drugs Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL ANTITUSSIVE DRUGS MARKET: BY ROUTE OF ADMINISTRATION 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Route Of Administration
• 6.2. Oral Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Inhalational Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL ANTITUSSIVE DRUGS MARKET: BY DOSAGE FORM 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast Dosage Form
• 7.2. Syrup Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Tablet Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL ANTITUSSIVE DRUGS MARKET: BY INDICATION 2022-2034 (USD MN)

• 8.1. Market Analysis, Insights and Forecast Indication
• 8.2. Cold Symptoms Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.3. Pain Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.4. Cough Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 9. GLOBAL ANTITUSSIVE DRUGS MARKET: BY PRODUCT TYPE 2022-2034 (USD MN)

• 9.1. Market Analysis, Insights and Forecast Product Type
• 9.2. Over-The-counter (OTC) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 9.3. Prescription Drug Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 10. GLOBAL ANTITUSSIVE DRUGS MARKET: BY AGE GROUP 2022-2034 (USD MN)

• 10.1. Market Analysis, Insights and Forecast Age Group
• 10.2. Pediatric Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 10.3. Adult Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 10.4. Geriatric Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 11. GLOBAL ANTITUSSIVE DRUGS MARKET: BY END-USERS 2022-2034 (USD MN)

• 11.1. Market Analysis, Insights and Forecast End-users
• 11.2. Hospitals Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 11.3. Specialty Clinics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 11.4. Homecare Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 11.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 12. GLOBAL ANTITUSSIVE DRUGS MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

• 12.1. Market Analysis, Insights and Forecast Distribution Channel
• 12.2. Hospital Pharmacy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 12.3. Retail Pharmacy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 12.4. Online Pharmacy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 12.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 13. GLOBAL ANTITUSSIVE DRUGS MARKET: BY REGION 2022-2034 (USD MN)

• 13.1. Regional Outlook
• 13.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 13.2.1 By Drug
  • 13.2.2 By Drug Class
  • 13.2.3 By Route Of Administration
  • 13.2.4 By Dosage Form
  • 13.2.5 By Indication
  • 13.2.6 By Product Type
  • 13.2.7 By Age Group
  • 13.2.8 By End-users
  • 13.2.9 By Distribution Channel
  • 13.2.10 United States
  • 13.2.11 Canada
  • 13.2.12 Mexico
• 13.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 13.3.1 By Drug
  • 13.3.2 By Drug Class
  • 13.3.3 By Route Of Administration
  • 13.3.4 By Dosage Form
  • 13.3.5 By Indication
  • 13.3.6 By Product Type
  • 13.3.7 By Age Group
  • 13.3.8 By End-users
  • 13.3.9 By Distribution Channel
  • 13.3.10 United Kingdom
  • 13.3.11 France
  • 13.3.12 Germany
  • 13.3.13 Italy
  • 13.3.14 Russia
  • 13.3.15 Rest Of Europe
• 13.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 13.4.1 By Drug
  • 13.4.2 By Drug Class
  • 13.4.3 By Route Of Administration
  • 13.4.4 By Dosage Form
  • 13.4.5 By Indication
  • 13.4.6 By Product Type
  • 13.4.7 By Age Group
  • 13.4.8 By End-users
  • 13.4.9 By Distribution Channel
  • 13.4.10 India
  • 13.4.11 Japan
  • 13.4.12 South Korea
  • 13.4.13 Australia
  • 13.4.14 South East Asia
  • 13.4.15 Rest Of Asia Pacific
• 13.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 13.5.1 By Drug
  • 13.5.2 By Drug Class
  • 13.5.3 By Route Of Administration
  • 13.5.4 By Dosage Form
  • 13.5.5 By Indication
  • 13.5.6 By Product Type
  • 13.5.7 By Age Group
  • 13.5.8 By End-users
  • 13.5.9 By Distribution Channel
  • 13.5.10 Brazil
  • 13.5.11 Argentina
  • 13.5.12 Peru
  • 13.5.13 Chile
  • 13.5.14 Rest of Latin America
• 13.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 13.6.1 By Drug
  • 13.6.2 By Drug Class
  • 13.6.3 By Route Of Administration
  • 13.6.4 By Dosage Form
  • 13.6.5 By Indication
  • 13.6.6 By Product Type
  • 13.6.7 By Age Group
  • 13.6.8 By End-users
  • 13.6.9 By Distribution Channel
  • 13.6.10 Saudi Arabia
  • 13.6.11 UAE
  • 13.6.12 Israel
  • 13.6.13 South Africa
  • 13.6.14 Rest of the Middle East And Africa

Chapter 14. COMPETITIVE LANDSCAPE

• 14.1. Recent Developments
• 14.2. Company Categorization
• 14.3. Supply Chain & Channel Partners (based on availability)
• 14.4. Market Share & Positioning Analysis (based on availability)
• 14.5. Vendor Landscape (based on availability)
• 14.6. Strategy Mapping

Chapter 15. COMPANY PROFILES OF GLOBAL ANTITUSSIVE DRUGS INDUSTRY

• 15.1. Top Companies Market Share Analysis
• 15.2. Company Profiles
  • 15.2.1 F. Hoffmann-La Roche Ltd
  • 15.2.2 Pfizer Inc
  • 15.2.3 Novartis AG
  • 15.2.4 GlaxoSmithKline Plc
  • 15.2.5 Sanofi
  • 15.2.6 Johnson & Johnson Private Limited
  • 15.2.7 Teva Pharmaceutical Industries Ltd
  • 15.2.8 Sun Pharmaceutical Industries Ltd
  • 15.2.9 Mylan N.V
  • 15.2.10 AstraZeneca
  • 15.2.11 Bayer AG
  • 15.2.12 Cipla Inc
  • 15.2.13 Aurobindo Pharma
  • 15.2.14 Hikma Pharmaceuticals PLC
  • 15.2.15 Amneal Pharmaceuticals LLC